RADNOR, Pa., March 26, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that it will release its fourth quarter and full year
2023 financial results after the market closes on Thursday, March 28, 2024, via press release,
which will be available on the Company's website at
https://ir.nrxpharma.com/press-releases. Due to scheduling
conflicts and the Good Friday stock market holiday, the Company
will now host its conference call to discuss the financial results
as well as provide a corporate update on Monday, April 1, 2024, at 8:30 a.m. ET.
A live webcast of the conference call will be available on the
Company's website at https://ir.nrxpharma.com/events.
Participants that are unable to join the webcast can access the
conference call via telephone by dialing domestically
+1-877-704-4453 or internationally +1-201-389-0920.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen and Lotus around the
development and marketing of NRX-101 for the treatment of suicidal
bipolar depression. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for HTX-100 (IV ketamine), through Hope Therapeutics,
in the treatment of suicidal depression, based on results of
well-controlled clinical trials conducted under the auspices of the
US National Institutes of Health and newly obtained data from
French health authorities, licensed under a data sharing agreement.
NRx was awarded Fast Track Designation for development of ketamine
(NRX-100) by the US FDA as part of a protocol to treat patients
with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc.
(www.hopetherapeutics.com) is a Specialty Pharmaceutical Company,
wholly-owned by NRX Pharmaceuticals focused on development and
marketing of an FDA-approved form of intravenous ketamine for the
treatment of acute suicidality and depression together with a
digital therapeutic-enabled platform designed to augment and
preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The
information contained herein includes forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended, and Section 27A of the Securities Act of 1933, as
amended. These statements include, among others, statements
regarding the proposed public offering and the timing and the use
of the proceeds from the offering. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as "may," "will," "should," "would," "expect," "plan,"
"believe," "intend," "look forward," and other similar expressions
among others. These statements relate to future events or to the
Company's future financial performance, and involve known and
unknown risks, uncertainties and other factors that may cause the
Company's actual results to be materially different from any future
results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. Any forward-looking
statement reflects the Company's current views with respect to
future events and is subject to these and other risks,
uncertainties and assumptions relating to the Company's operations,
results of operations, growth strategy and liquidity. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company's most recent Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission. Investors and security
holders are urged to read these documents free of charge on the
SEC's website at http://www.sec.gov. Except as may be required
by applicable law, The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, whether
as a result of new information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/update-nrx-pharmaceuticals-nasdaq-nrxp-to-report-fourth-quarter-and-full-year-2023-financial-results-on-march-28-2024-302100135.html
SOURCE NRx Pharmaceuticals, Inc.